股票 › ABUS
阿布图斯生物制药 ABUS
美股市值排名 #3432
$3.66 −$0.02 (-0.41%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $3.65 -0.14%
开盘$3.65
昨收$3.67
当日区间$3.62 – $3.75
成交量1.72M
市值$724.08M
市盈率（TTM）4.6
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$1.01M-90.6% YoY
营业利润-$5.75M-400.6% YoY
净利润-$5.14M-303.8% YoY
摊薄每股收益-$0.03-400.0% YoY
自由现金流-$6.02M+61.8% YoY
经营现金流-$6.02M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
营业利润率81.1%
净利率84.2%
净资产收益率89.6%
资产收益率81.1%
投入资本回报率88.0%
流动比率81.42
负债/资产比率5.6%
现金及投资$92.63M
总负债$0.00
净现金（净负债）$92.63M
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $1.01M | $179.13M | $14.08M | $1.05M | $529,000.00 |
| 营业总收入 | $1.01M | $179.13M | $14.08M | $1.05M | $529,000.00 |
| 营业费用 | $6.77M | $10.01M | $41.13M | $8.70M | $8.82M |
| 销售及管理费用 | $3.87M | $5.89M | $15.89M | $3.69M | $3.04M |
| -管理费用 | $3.87M | $5.89M | $15.89M | $3.69M | $3.04M |
| 研发费用 | $2.90M | $4.12M | $25.24M | $5.01M | $5.78M |
| 营业利润 | -$5.75M | $169.12M | -$27.05M | -$7.64M | -$8.29M |
| 非经营性利息净收入（支出） | $824,000.00 | $798,000.00 | $3.97M | $859,000.00 | $929,000.00 |
| 非经营性利息收入 | $842,000.00 | $815,000.00 | $4.07M | $877,000.00 | $952,000.00 |
| 非经营性利息支出 | $18,000.00 | $17,000.00 | $97,000.00 | $18,000.00 | $23,000.00 |
| 其他收入（支出） | -$216,000.00 | -$220,000.00 | -$10.42M | $3.03M | -$378,000.00 |
| 证券出售收益 | -$3,000.00 | -$11,000.00 | $14,000.00 | $1,000.00 | -$12,000.00 |
| 特殊收益（费用） | -$213,000.00 | -$209,000.00 | -$10.44M | $3.03M | -$366,000.00 |
| -减：重组及并购费用 | $213,000.00 | $209,000.00 | $11.11M | -$2.35M | $366,000.00 |
| 税前利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 净利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 持续经营利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 归属母公司净利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 归属普通股股东净利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 基本每股收益 | -$0.03 | $0.88 | -$0.17 | -$0.01 | -$0.04 |
| 摊薄每股收益 | -$0.03 | $0.87 | -$0.17 | -$0.01 | -$0.04 |
| -固定资产出售收益 | – | – | $674,000.00 | – | – |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $274.03M | $277.16M | $94.62M | $94.62M | $97.71M |
| 流动资产合计 | $273.88M | $277.01M | $94.46M | $94.46M | $97.44M |
| 现金及现金等价物与短期投资 | $92.63M | $95.23M | $91.47M | $91.47M | $93.70M |
| -现金及现金等价物 | $19.17M | $23.71M | $18.01M | $18.01M | $22.41M |
| -短期投资 | $73.45M | $71.52M | $73.46M | $73.46M | $71.29M |
| 应收款 | $179.74M | $180.05M | $1.45M | $1.45M | $905,000.00 |
| -应收账款 | $369,000.00 | $1.31M | $1.45M | $1.45M | $905,000.00 |
| -其他应收款 | $179.37M | $178.74M | – | – | – |
| 其他流动资产 | $1.52M | $1.73M | $1.54M | $1.54M | $2.84M |
| 非流动资产合计 | $142,000.00 | $153,000.00 | $162,000.00 | $162,000.00 | $268,000.00 |
| 固定资产净值 | $10,000.00 | $22,000.00 | $32,000.00 | $32,000.00 | $137,000.00 |
| -固定资产原值 | $245,000.00 | $246,000.00 | $245,000.00 | $245,000.00 | $13.48M |
| -累计折旧 | -$235,000.00 | -$224,000.00 | -$213,000.00 | -$213,000.00 | -$13.35M |
| 其他非流动资产 | $132,000.00 | $131,000.00 | $130,000.00 | $130,000.00 | $131,000.00 |
| 负债合计 | $15.29M | $16.99M | $18.04M | $18.04M | $20.31M |
| 流动负债合计 | $3.36M | $5.11M | $6.01M | $6.01M | $5.18M |
| 应付款 | $373,000.00 | $1.46M | $1.17M | $1.17M | $1.01M |
| -应付账款 | $373,000.00 | $1.46M | $1.17M | $1.17M | $1.01M |
| 一年内应计费用 | $2.32M | $2.77M | $3.65M | $3.65M | $2.88M |
| 短期债务及融资租赁负债 | $514,000.00 | $631,000.00 | $547,000.00 | $547,000.00 | $531,000.00 |
| -一年内到期融资租赁负债 | $514,000.00 | $631,000.00 | $547,000.00 | $547,000.00 | $531,000.00 |
| 其他流动负债 | $160,000.00 | $245,000.00 | $640,000.00 | $640,000.00 | $763,000.00 |
| 非流动负债合计 | $11.93M | $11.88M | $12.04M | $12.04M | $15.13M |
| 长期债务及融资租赁负债 | $0.00 | $0.00 | $199,000.00 | $199,000.00 | $391,000.00 |
| -长期融资租赁负债 | $0.00 | $0.00 | $199,000.00 | $199,000.00 | $391,000.00 |
| 其他非流动负债 | $11.93M | $11.88M | $11.84M | $11.84M | $14.74M |
| 股东权益合计 | $258.73M | $260.18M | $76.58M | $76.58M | $77.40M |
| 股东权益 | $258.73M | $260.18M | $76.58M | $76.58M | $77.40M |
| 股本 | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B |
| -普通股 | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B |
| 资本公积 | $74.32M | $74.26M | $83.32M | $83.32M | $83.29M |
| 留存收益 | -$1.22B | -$1.21B | -$1.38B | -$1.38B | -$1.38B |
| 不影响留存收益的损益 | -$48.24M | -$48.20M | -$48.10M | -$48.10M | -$48.13M |
| 一年内递延负债 | – | – | $0.00 | $0.00 | $0.00 |
| 一年以上递延负债 | – | – | $0.00 | $0.00 | $0.00 |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | -$6.02M | -$8.11M | -$39.64M | -$4.68M | -$5.82M |
| 持续经营经营活动现金流净额 | -$6.02M | -$8.11M | -$39.64M | -$4.68M | -$5.82M |
| 持续经营净利润 | -$5.14M | $169.70M | -$33.50M | -$3.76M | -$7.74M |
| 折旧、折耗与摊销 | $11,000.00 | $11,000.00 | $363,000.00 | $11,000.00 | $11,000.00 |
| 其他非现金项目 | $46,000.00 | $45,000.00 | -$3.22M | -$2.90M | $42,000.00 |
| 营运资金变动 | -$2.24M | -$178.87M | -$10.02M | $1.80M | $1.15M |
| -应收款变动 | -$179.46M | $1.16M | $1.38M | -$129,000.00 | $120,000.00 |
| -预付资产变动 | $215,000.00 | -$195,000.00 | $1.70M | $1.30M | $1.04M |
| -应付账款及应计费用变动 | -$1.62M | -$985,000.00 | -$2.11M | $806,000.00 | $145,000.00 |
| -其他流动负债变动 | -$113,000.00 | -$105,000.00 | -$557,000.00 | -$177,000.00 | -$155,000.00 |
| 投资活动现金流净额 | -$1.66M | $2.20M | $15.58M | -$1.36M | -$10.02M |
| 持续经营投资活动现金流净额 | -$1.66M | $2.20M | $15.58M | -$1.36M | -$10.02M |
| 投资购置及出售净额 | -$1.66M | $2.20M | $15.22M | -$1.72M | -$10.02M |
| 筹资活动现金流 | $3.15M | $11.62M | $5.72M | $1.64M | $844,000.00 |
| 持续经营筹资活动现金流净额 | $3.15M | $11.62M | $5.72M | $1.64M | $844,000.00 |
| 股票期权行使所得 | $3.15M | $11.62M | $5.72M | $1.64M | $844,000.00 |
| 期末现金余额 | $19.17M | $23.71M | $18.01M | $18.01M | $22.41M |
| 现金净变动 | -$4.53M | $5.71M | -$18.34M | -$4.40M | -$14.99M |
| 期初现金余额 | $23.71M | $18.01M | $36.33M | $22.41M | $37.41M |
| 汇率变动影响 | -$4,000.00 | -$10,000.00 | $14,000.00 | $1,000.00 | -$12,000.00 |
| 自由现金流 | -$6.02M | -$8.11M | -$39.64M | -$4.68M | -$5.82M |
| -其他营运资金变动 | – | -$178.74M | -$10.43M | $0.00 | $0.00 |
| 其他投资变动净额 | – | -$1,000.00 | – | – | – |
| 持续经营损益 | – | – | -$674,000.00 | – | – |
| 固定资产购置及出售净额 | – | – | $364,000.00 | $355,000.00 | $0.00 |
| 普通股发行净额 | – | – | $0.00 | $0.00 | – |
暂无评论——快来第一个聊聊 ABUS。
登录后参与讨论。